Hereby, patients with metastatic prostate cancer based on conventional or PSMA-PET/CT based imaging are randomized into local therapy (RP or radiotherapy of the prostate) arm or a control arm while both arms undergo standard of care systemic androgen deprivation therapies. This evidence concerns the gene FOLH1 and metastatic prostate carcinoma.